Abstract: The disclosure provides a lyophilized preparation of prostaglandin E1 methyl ester for injection and production and use thereof. The lyophilized preparation comprises the following components by weight: 0.1-10 parts of prostaglandin E1 methyl ester, 500-4000 parts of an oil for injection, 500-2000 parts of an emulsifier, 0-10 parts of a co-emulsifier, 5000-50000 parts of a lyoprotectant, and 200-1500 parts of glycerin. The prostaglandin E1 methyl ester lyophilized agent of the disclosure has less blood vessel irritation, good drug stability, and superior drug activity and therapeutic effect than similar prostaglandin E1 products.

Abstract: The present invention provides formulations that enhances bioavailability of thromboxane receptor antagonists allowing them to bind to the thromboxane A2 receptors in subjects suffering from disease indications in which the prostanoid thromboxane A2, and incidental thromboxane A2 receptor ligands, are implicated. The formulations comprise a solid dispersion comprising a benzenesulfonyl urea and a polymer that are suitable for administration through oral or other routes of delivery.

Abstract: The present invention provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders. Variables rings A, B, R1, R3, R8, and other variables are as defined herein.

Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.

Abstract: The invention provides a process for the preparation of cyclosporin derivatives.

Abstract: The present disclosure encompasses solid state forms of AT-001, in embodiments crystalline polymorphs of AT-001 or salts or co-crystals of AT-001, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: Compositions comprising aldehyde functional monoterpenoids in combination with 3,3?,4?,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19, and/or enhancing mood.

Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, ?-lactamase inhibitors (BLIs).

Abstract: 1. The present invention relates to the crystal of compound X7 hydrochloride and its preparation method and application. The 2? diffraction angle of the X-ray powder diffraction diagram of the crystal of compound X7 hydrochloride exhibits characteristic diffraction peaks in the range of 5°˜35°. The crystal of the compound X7 hydrochloride has better physical and chemical properties.

Abstract: The present invention provides compounds of formula I or II: wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2 , or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.

Abstract: A compound of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treatment or prevention of human immunodeficiency virus (HIV) infection are set forth. Novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection are described.

Abstract: Provided herein are compounds (e.g., compounds of Formula (Ia)) that function to recruit LRRK2 protein or a mutated version thereof to an E3 ubiquitin ligase for targeted ubiquitination and subsequent proteasomal degradation.

Abstract: There is provided a composition for topical application to the penis for the treatment of erectile dysfunction, the composition being free of glyceryl trinitrate (GTN), sildenafil and an acetylcholinesterase inhibitor, and comprising volatile and non-volatile solvents, the volatile solvents comprising a lower alcohol and water and the non-volatile solvents comprising a polyhydric alcohol and a glycol. Preferably, the composition does not contain any pharmaceutically active ingredients for the treatment of erectile dysfunction. Also provided is a method of determining the cooling ability of a test composition, such as the composition described above.

Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: Antifibrinolytic agents/drugs are applied to the concussive area of a patient's brain to counter the activation of a fibrinolytic process in the concussive area. Various techniques are described for administering the antifibrinolytic agent.

Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

Abstract: The present invention relates to a composition for the prevention, amelioration, or treatment of urination-related disases, comprising cephalotocin. The cephalotocin according to the present invention modulates oxytocin receptors and vasopressin receptors, and has the effect of reducing urine volume by promoting water reabsorption in the kidneys. This means that cephalotocin has a significant antidiuretic effect, and thus, the cephalotocin of the present invention can be variously used in the field of prevention, amelioration, or treatment of urinary disorders or urination-related diseases.

Abstract: The present disclosure relates generally to methods of treating infections in overweight or obese patients using antibiotics.